San MediTech Showcases Smart Glucose Management Cloud Database at 75th ADA

BEIJING, June 2, 2015 /PRNewswire/ -- San MediTech, the industry leader in China for continuous glucose monitoring (CGM) for diabetics, announced its plan to attend the American Diabetes Association (ADA) 75th Scientific Sessions in Boston on June 5^th to 8^th and present their newest Dynamic Glucose Monitoring System (DGMS). The company plans to show industry experts and academics from around the world the innovative technologies and advancements made by Chinese medical device companies. San MediTech will also unveil the world's first data platform dedicated to diabetes management through continuous glucose monitoring.

San MediTech CGM: the integration of smart wearable devices and a big data health platform

As the only CGM company in China, San MediTech plans to showcase an innovative product: a novel Bluetooth CGM transmitter and mini-sensor. The device requires no dedicated receiver, and patients and doctors can view data on a smartphone. The showcase will take place at Booth 221 in the Boston Convention and Exhibition Center in Massachusetts. The San MediTech CGM is the world's first dynamic glucose monitoring ecosystem. A simple, user-friendly app delivers medical data and receives news, tips, and advice from professionals. The system combines sensor and mobile communication technologies with big data analysis.

San MediTech will also show the results of research based on data mining of existing glucose data. This research highlights the transformation of San MediTech from a traditional medical device manufacturer to one based on research, service, and complete disease management. This research also heralds the arrival of the era when diabetes monitoring technology is combined with big data analysis as a means to determine the best options for treatment.

This wearable device is light, simple to apply and remove, and small in size. The patient wears the device on the upper arm. After inserting the sensor, accurate glucose readings are collected 24 hours per day and are automatically displayed on a smartphone via a Bluetooth connection. The SMT app also sends automated glucose threshold alerts, enabling doctors and patients to evaluate glucose trends and take appropriate precautions. This mitigates the effect of diabetes, and minimizes the likelihood of excursion-related complications.

The CGM system can also store exercise, diet, medication, location, and mood. This data, along with glucose levels, is uploaded via cellular networks or wireless Internet connections, allowing patients to share their data with health care practitioners, friends, and family. Data recipients and doctors can also communicate directly with the patient, should this be necessary.

San MediTech: the industry leader in China's glucose monitoring technology

This is the fifth time that San MediTech has attended the ADA. San MediTech plans to take advantage of the opportunity to enhance brand visibility, raise global awareness across the sector of the company's products and services, as well as expand global partnerships.

"We are honored to participate in the ADA as the event is the world's highest-level symposium in the research area of diabetes," said Hao Gang, chairman of San MediTech. "The San MediTech CGM presented at this ADA is a new mobile wearable medical device. Patients can monitor their glucose data anytime and anywhere through an app they can download to their cellphone. We are looking forward to improving communication with partners via this platform, enabling them to have a thorough understanding of San MediTech's powerful technology and service capabilities while jointly exploring cooperation opportunities in this era of mobile medical data."

Contributing to China's "One Belt, One Road" strategy, while caring for maternal and infant health

The proportion of gestational diabetes is rising. In 2013 alone, nearly 21 million newborns were born to mothers affected by gestational diabetes (GDM). San MediTech has been paying close attention to GDM and has conducted research on hyperglycaemia during pregnancy in recent years.

The new San MediTech CGM is a welcome solution for pregnant women with glucose control issues, or for mothers who have previously given birth to babies with fetal macrosomia. CGM also streamlines the monitoring of glucose levels throughout pregnancy, and minimizes the resources required by a hospital to conduct glucose tests. With CGM, hospitals and pregnant women have access to a 24-hour curve and can immediately measure the impact of diet, exercise and lifestyle on glucose levels.

In response to a request from the government, San MediTech donated the most advanced gestational diabetes monitoring platform and equipment to hospitals in the Xinjiang Uygur Autonomous Region. This area in northwest China is key to the roll out of China's One Belt and One Road economic strategy. This platform brings together best-practices provided by the Endocrinology Department of Peking Union Medical College Hospital, and remote management of GDM via San MediTech's CGM. The remote link-up officially went online on World Diabetes Day 2014.

San MediTech and its partners also joined hands with the China Welfare Institute in proposing the establishment of a CGM-based program for maternal and infant healthcare as part of the One Belt, One Road Medical Financial Assistance initiative, aimed at extending the program beyond Xinjiang as a means to provide better personalized medical services for pregnant women in the countries along the Silk Road Economic Belt."We will keep innovating our products and services so that diabetic patients the world over can benefit from this business model," said Hao Gang.

About San MediTech

San MediTech, founded in 2003, is a medical device company specializing in Dynamic Glucose Monitoring products, for which it holds several world-leading patents and technologies. The company has developed Dynamic Glucose Monitoring products for both hospitals and individuals to serve specific uses. These devices help diabetics benefit from the world's most advanced glucose monitoring technology.

About ADA

The American Diabetes Association's Scientific Sessions is the largest diabetes meeting in the world, bringing together thousands of participants from America and the world-including experts, professors, clinicians and researchers. The latest research findings from every corner of the world and famous universities and research institutes in America will be presented at the sessions. The ADA Sessions, a wind vane in the prevention and cure of diabetes worldwide, is the top-level seminar in diabetes research area. At the sessions, industry experts, professors and attendees will exchange latest information about diabetes research, their views, opinions, comments and information about their ongoing scientific research activities in their labs. 

SOURCE San MediTech